Prostate cancer cells synergistically defend against CD8+ T cells by secreting exosomal PD‐L1

Prostate cancer cells synergistically defend against CD8+ T cells by secreting exosomal PD‐L1

Abstract Background Metastatic castration‐resistant prostate cancer (mCRPC) remains fatal and incurable, despite a variety of treatments that can delay disease progression and prolong life. Immune checkpoint therapy is a promising treatment. However, emerging evidence suggests that exosomal programm...

Full description

Bibliographic Details
Main Authors:	Dameng Li, Xueying Zhou, Wenxian Xu, Yuxin Chen, Chenglong Mu, Xinchun Zhao, Tao Yang, Gang Wang, Liang Wei, Bo Ma
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	Cancer Medicine
Subjects:	anti‐PD‐L1 therapy CD8+ T cells exosomes PD‐L1 prostate cancer
Online Access:	https://doi.org/10.1002/cam4.6275

Similar Items

Effect of Rapamycin on Exosomes and PD-1/PD-L1 in Human Erythroleukemia HEL Cells
by: QI Lin, et al.
Published: (2022-10-01)

The role of exosomal PD-L1 in tumor progression and immunotherapy
by: Feiting Xie, et al.
Published: (2019-10-01)

Research Advances of Immunotherapy of Exosome PD-L1  in Non-small Cell Lung Cancer
by: Na WANG, et al.
Published: (2022-09-01)

Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients
by: Marine Cordonnier, et al.
Published: (2020-01-01)

Effects of Tumor-Derived Exosome Programmed Death Ligand 1 on Tumor Immunity and Clinical Applications
by: Bo Shao, et al.
Published: (2021-10-01)

The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target
by: Lingxiao Ye, et al.
Published: (2021-11-01)

The link between intracellular calcium signaling and exosomal PD-L1 in cancer progression and immunotherapy
by: Md Rakibul Alam, et al.
Published: (2024-01-01)

Mutual regulation of PD-L1 immunosuppression between tumor-associated macrophages and tumor cells: a critical role for exosomes
by: Banglu Wang, et al.
Published: (2024-01-01)

The immune checkpoint regulator PD-L1 expression are associated with clinical progression in prostate cancer
by: Juan He, et al.
Published: (2021-07-01)

LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer
by: Dan-Dan Shen, et al.
Published: (2022-03-01)

The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection
by: Kristen E. Pauken, et al.
Published: (2020-06-01)

Exosomal PD-L1 induces osteogenic differentiation and promotes fracture healing by acting as an immunosuppressant
by: Ze Lin, et al.
Published: (2022-07-01)

Tumor‐derived exosomal PD-L1: a new perspective in PD-1/PD-L1 therapy for lung cancer
by: Yunjiao Wu, et al.
Published: (2024-03-01)

Regulation of Immunity in Clear Cell Renal Carcinoma: Role of PD-1, PD-L1, and PD-L2
by: Liudmila Spirina, et al.
Published: (2021-09-01)

The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer
by: Yanyan Tang, et al.
Published: (2020-04-01)

PD-1 and PD-L1 expression predict regression and prognosis following neoadjuvant radiochemotherapy of oesophageal adenocarcinoma
by: Holger H. Göbel, et al.
Published: (2022-05-01)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
by: Mengling Wu, et al.
Published: (2022-03-01)

High Quality Performance of Novel Immunoassays for the Sensitive Quantification of Soluble PD-1, PD-L1 and PD-L2 in Blood
by: Kimberly Krueger, et al.
Published: (2022-09-01)

The PD-1/PD-L1 Pathway Affects the Expansion and Function of Cytotoxic CD8+ T Cells During an Acute Retroviral Infection
by: Paul David, et al.
Published: (2019-02-01)

The Efficacy of PD-1/PD-L1 Inhibitors in Patients with Liver Metastasis of Non-Small Cell Lung Cancer: A Real-World Study
by: Mingying Xie, et al.
Published: (2022-09-01)

Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma
by: ZOU Hanhui, et al.
Published: (2020-02-01)

Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment
by: Chen Chen, et al.
Published: (2021-06-01)

Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Inﬂuenza A (H1N1)
by: A. V. Malyarchikov, et al.
Published: (2021-08-01)

Diagnostic Performance of PD-L1 versus PD-1 Expression in Circulating CD20 Cells in Diffuse Large B-Cell Lymphoma
by: Manal Mohamed Saber
Published: (2022-02-01)

Advances in the Influence of EGFR Mutation on the PD-L1 Expression in Non-small Cell Lung Cancer
by: Xiaoyu ZHI, et al.
Published: (2019-12-01)

Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance
by: Maria-Luisa del Rio, et al.
Published: (2022-06-01)

PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome
by: Sandra Lassalle, et al.
Published: (2020-11-01)

Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model
by: Eun-Ji Lee, et al.
Published: (2021-09-01)

The clinical association of programmed death-1/PD-L1 axis, myeloid derived suppressor cells subsets and regulatory T cells in peripheral blood of stable COPD patients
by: Mingqiang Zhang, et al.
Published: (2024-03-01)

Progress of exosomal PD-L1 in diagnosis and treatment of non-small cell lung cancer
by: YAN Chenhong, JIN Er
Published: (2023-09-01)

Robust Preanalytical Performance of Soluble PD-1, PD-L1 and PD-L2 Assessed by Sensitive ELISAs in Blood
by: Kimberly Krueger, et al.
Published: (2022-10-01)

PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
by: Min Luo, et al.
Published: (2021-10-01)

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
by: Hongbo Zhang, et al.
Published: (2021-06-01)

The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis
by: Yan Li, et al.
Published: (2019-01-01)

TGFβ-dependent expression of PD-1 and PD-L1 controls CD8+ T cell anergy in transplant tolerance
by: Marije Baas, et al.
Published: (2016-01-01)

Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma
by: Seok Jin Kim, et al.
Published: (2022-11-01)

Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer
by: Ching-Yao Yang, et al.
Published: (2020-06-01)

PD‐1/PD‐L1 based immunochemotherapy versus chemotherapy alone for advanced esophageal squamous cell carcinoma: A meta‐analysis focus on PD‐L1 expression level
by: Zixian Jin, et al.
Published: (2023-07-01)

Meta-analysis of the correlation between glioma prognosis and PD-1/PD-L1 expression
by: Chang-cheng Ren, et al.
Published: (2023-12-01)

Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade
by: Oliver Kepp, et al.
Published: (2019-10-01)